Related references
Note: Only part of the references are listed.Clinically relevant QTc prolongation is not associated with current dose schedules of LBH589 (panobinostat)
Lei Zhang et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Histone deacetylase inhibitors induce growth arrest and apoptosis of HTLV-1-infected T-cells via blockade of signaling by nuclear factor κB
Chie Nishioka et al.
LEUKEMIA RESEARCH (2008)
Combined effects of histone deacetylase inhibitor and rituximab on non-Hodgkin's B-lymphoma cells apoptosis
Wei-Li Zhao et al.
EXPERIMENTAL HEMATOLOGY (2007)
Epigenetic targets in hematological malignancies: Combination therapies with HDACis and demethylating agents
Mark Bishton et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2007)
Suberoylanilide hydroxamic acid (SAHA; vorinostat) suppresses translation of cyclin D1 in mantle cell lymphoma cells
Norihiko Kawamata et al.
BLOOD (2007)
Histone deacetylase inhibitors: Overview and perspectives
Milos Dokmanovic et al.
MOLECULAR CANCER RESEARCH (2007)
Histone deacetylase inhibitors: molecular mechanisms of action
W. S. Xu et al.
ONCOGENE (2007)
Sequence-dependent antitumor effects of differentiation agents in combination with cell cycle-dependent cytotoxic drugs
Henk M. W. Verheul et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2007)
Molecularly targeted oncology therapeutics and prolongation of the QT interval
Elizabeth L. Strevel et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Phase IIB multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma
Elise A. Olsen et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Multiple molecular pathways explain the anti-proliferative effect of valproic acid on prostate cancer cells InVitro and InVivo
Shabana Shabbeer et al.
PROSTATE (2007)
Phase I and pharmacokinetic study of vorinostat, A histone deacetylase inhibitor, in combination with carboplatin and paclitaxel for advanced solid malignancies
Suresh S. Ramalingam et al.
CLINICAL CANCER RESEARCH (2007)
Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors:: A clinical and translational study
Pamela Muenster et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Analysis of the apoptotic and therapeutic activities of histone deacetylase inhibitors by using a mouse model of B cell lymphoma
R. K. Lindemann et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Histone deacetylase inhibitors: Molecular and biological activity as a premise to clinical application
V. Santini et al.
CURRENT DRUG METABOLISM (2007)
Histone deacetylase inhibitors in cancer therapy
Walid K. Rasheed et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2007)
Vorinostat for treatment of cutaneous manifestations of advanced primary cutaneous T-cell lymphoma
Bhupinder S. Mann et al.
CLINICAL CANCER RESEARCH (2007)
Apoptosis induced by depsipeptide FK228 coincides with inhibition of survival signaling in lung cancer cells
Xiao-Dan Yu et al.
CANCER JOURNAL (2007)
Dimethyl sulfoxide to vorinostat: Development of this histone deacetylase inhibitor as an anticancer drug
Paul A. Marks et al.
NATURE BIOTECHNOLOGY (2007)
Suberoylanilide hydroxamic acid (vorinostat) represses androgen receptor expression and acts synergistically with an androgen receptor antagonist to inhibit prostate cancer cell proliferation
Deborah L. Marrocco et al.
MOLECULAR CANCER THERAPEUTICS (2007)
Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma, (CTCL)
Madeleine Duvic et al.
BLOOD (2007)
Histone deacetylase inhibitors and demethylating agents: Clinical development of histone deacetylase inhibitors for cancer therapy
Richard L. Piekarz et al.
CANCER JOURNAL (2007)
Valproic acid enhances tubulin acetylation and apoptotic activity of paclitaxel on anaplastic thyroid cancer cell lines
Maria G. Catalano et al.
ENDOCRINE-RELATED CANCER (2007)
Development of histone deacetylase inhibitors for cancer treatment
Douglas Marchion et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2007)
Sirtuins as potential targets for metabolic syndrome
Leonard Guarente
NATURE (2006)
Valproic acid, a histone deacetylase inhibitor, enhances sensitivity to doxorubicin in anaplastic thyroid cancer cells
Maria G. Catalano et al.
JOURNAL OF ENDOCRINOLOGY (2006)
Antitumor activity of suberoylanilide hydroxamic acid against thyroid cancer cell lines in vitro and in vivo
Quang T. Luong et al.
CLINICAL CANCER RESEARCH (2006)
Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer
Michael A. Carducci et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
The selectivty and anti-metastatic activity of oral bioavailable butyric acid prodrugs
A Rephaeli et al.
INVESTIGATIONAL NEW DRUGS (2006)
Phase I study of depsipeptide in pediatric patients with refractory solid tumors: A children's oncology group report
Maryam Fouladi et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Cardiotoxicity of histone deacetylase inhibitor depsipeptide in patients with metastatic neuroendocrine tumors
Manisha H. Shah et al.
CLINICAL CANCER RESEARCH (2006)
Gemcitabine plus CI-994 offers no advantage over gemcitabine alone in the treatment of patients with advanced pancreatic cancer: results of a phase II randomized, double-blind, placebo-controlled, multicenter study
D. A. Richards et al.
ANNALS OF ONCOLOGY (2006)
Cardiac studies in patients treated with depsipeptide, FK228, in a phase II trial for T-cell lymphoma
Richard L. Piekarz et al.
CLINICAL CANCER RESEARCH (2006)
A phase II study of depsipeptide in refractory metastatic renal cell cancer
Walter M. Stadler et al.
CLINICAL GENITOURINARY CANCER (2006)
Quantitative PCR on 5 genes reliably identifies CTCL patients with 5% to 99% circulating tumor cells with 90% accuracy
M Nebozhyn et al.
BLOOD (2006)
Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction?
SB Baylin et al.
NATURE REVIEWS CANCER (2006)
Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies
OA O'Connor et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Potential role of histone deacetylase inhibitors in mesothelioma: Clinical experience with suberoylanilide hydroxamic acid
Lee M. Krug et al.
CLINICAL LUNG CANCER (2006)
Bombesin/gastrin-releasing peptide receptor antagonists increase the ability of histone deacetylase inhibitors to reduce lung cancer proliferation
TW Moody et al.
JOURNAL OF MOLECULAR NEUROSCIENCE (2006)
Histone deacetylase inhibitors reduce VEGF production and induce growth suppression and apoptosis in human mantle cell lymphoma
U Heider et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2006)
Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer
S Minucci et al.
NATURE REVIEWS CANCER (2006)
Anticancer activities of histone deacetylase inhibitors
Jessica E. Bolden et al.
NATURE REVIEWS DRUG DISCOVERY (2006)
Targeted induction of apoptosis in cancer management: The emerging role of tumor necrosis factor-related apoptosis-inducing ligand receptor activating agents
EK Rowinsky
JOURNAL OF CLINICAL ONCOLOGY (2005)
Histone modifying enzymes and cancer: Going beyond histones
K Zhang et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2005)
Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous T-cell lymphoma cells: Relevance to mechanism of therapeutic action
CL Zhang et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2005)
Prospects: Histone deacetylase inhibitors
M Dokmanovic et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2005)
Suberoylanilide hydroxamic acid combined with gemcitabine enhances apoptosis in non-small cell lung cancer
BK Rundall et al.
SURGERY (2005)
Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies
KN Bhalla
JOURNAL OF CLINICAL ONCOLOGY (2005)
Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer
WK Kelly et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma
QC Ryan et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Epigenetic modulation of retinoic acid receptor β2 by the histone deacetylase inhibitor MS-275 in human renal cell carcinoma
XF Wang et al.
CLINICAL CANCER RESEARCH (2005)
Oral sodium phenylbutyrate in patients with recurrent malignant gliomas: A dose escalation and pharmacologic study
S Phuphanich et al.
NEURO-ONCOLOGY (2005)
Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer
MF Fraga et al.
NATURE GENETICS (2005)
Histone deacetylase inhibitors down-regulate bcl-2 expression and induce apoptosis in t(14;18) lymphomas
H Duan et al.
MOLECULAR AND CELLULAR BIOLOGY (2005)
Valproic acid induces apoptosis and cell cycle arrest in poorly differentiated thyroid cancer cells
MG Catalano et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2005)
Molecular evolution of the histone deacetylase family: Functional implications of phylogenetic analysis
IV Gregoretti et al.
JOURNAL OF MOLECULAR BIOLOGY (2004)
Phase II trial of the histone deacetylase inhibitor pivaloyloxymethyl butyrate (Pivanex, AN-9) in advanced non-small cell lung cancer
T Reid et al.
LUNG CANCER (2004)
A novel mechanism of chemoprotection by sulforaphane: Inhibition of histone deacetylase
MC Myzak et al.
CANCER RESEARCH (2004)
Histone deacetylase inhibitors potentiate TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in lymphoid malignancies
S Inoue et al.
CELL DEATH AND DIFFERENTIATION (2004)
Diallyl disulfide (DADS) increases histone acetylation and p21waf1/cip1 expression in human colon tumor cell lines
N Druesne et al.
CARCINOGENESIS (2004)
T-cell lymphoma as a model for the use of histone deacetylase inhibitors in cancer therapy: impact of depsipeptide on molecular markers, therapeutic targets, and mechanisms of resistance
RL Piekarz et al.
BLOOD (2004)
Phase I trial and pharmacokinetics of gemcitabine in children with advanced solid tumors
JM Reid et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
A phase I study of the oral combination of CI-994, a putative histone deacetylase inhibitor, and capecitabine
SD Undevia et al.
ANNALS OF ONCOLOGY (2004)
Selective efficacy of depsipeptide in a xenograft model of Epstein-Barr virus-positive lymphoproliferative disorder
S Roychowdhury et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2004)
Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis
P Zhu et al.
CANCER CELL (2004)
Phase I study of oral CI-994 in combination with carboplatin and paclitaxel in the treatment of patients with advanced solid tumors
LR Pauer et al.
CANCER INVESTIGATION (2004)
A study of a different dose-intense infusion schedule of phenylacetate in patients with recurrent primary brain tumors: a North American brain tumor consortium report
SM Chang et al.
INVESTIGATIONAL NEW DRUGS (2003)
Molecular pathogenesis of non-Hodgkin's lymphoma: The role of Bcl-6
L Pasqualucci et al.
LEUKEMIA & LYMPHOMA (2003)
Phase I study of oral CI-994 in combination with gemcitabine in treatment of patients with advanced cancer
JJ Nemunaitis et al.
CANCER JOURNAL (2003)
TNF-related apoptosis inducing ligand (TRAIL) and its receptors in tumor surveillance and cancer therapy
H Wajant et al.
APOPTOSIS (2002)
A histone deacetylase inhibitor enhances killing of undifferentiated thyroid carcinoma cells by p53 gene therapy
R Imanishi et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2002)
The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin
LM Butler et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Chromatin modification, leukaemia and implications for therapy
LK Jones et al.
BRITISH JOURNAL OF HAEMATOLOGY (2002)
Histone deacetylase inhibitors in cancer treatment
DM Vigushin et al.
ANTI-CANCER DRUGS (2002)
Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report
RL Piekarz et al.
BLOOD (2001)
Transcriptional regulation in acute promyelocytic leukemia
RJ Lin et al.
ONCOGENE (2001)
The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species
AA Ruefli et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Histone methylation versus histone acetylation: new insights into epigenetic regulation
JC Rice et al.
CURRENT OPINION IN CELL BIOLOGY (2001)
Histone acetylation and disease
S Timmermann et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2001)
Histone deacetylase inhibitors promote apoptosis and differential cell cycle arrest in anaplastic thyroid cancer cells
VL Greenberg et al.
THYROID (2001)
Chronic oral administration of CI-994: A phase 1 study
S Prakash et al.
INVESTIGATIONAL NEW DRUGS (2001)
Rapid induction of histone hyperacetylation and cellular differentiation in human breast tumor cell lines following degradation of histone deacetylase-1
Q Zhou et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation
VM Richon et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
Share Paper
